Wnt5A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells

We have previously shown that Wnt5A drives invasion in melanoma. We have also shown that Wnt5A promotes resistance to therapy designed to target the BRAFV600E mutation in melanoma. Here, we show that melanomas characterized by high levels of Wnt5A respond to therapeutic stress by increasing p21 and expressing classical markers of senescence, including positivity for senescence‐associated β‐galactosidase (SA‐β‐gal), senescence‐associated heterochromatic foci (SAHF), H3K9Me chromatin marks, and PML bodies. We find that despite this, these cells retain their ability to migrate and invade. Further, despite the expression of classic markers of senescence such as SA‐β‐gal and SAHF, these Wnt5A‐high cells are able to colonize the lungs in in vivo tail vein colony‐forming assays. This clearly underscores the fact that these markers do not indicate true senescence in these cells, but instead an adaptive stress response that allows the cells to evade therapy and invade. Notably, silencing Wnt5A reduces expression of these markers and decreases invasiveness. The combined data point to Wnt5A as a master regulator of an adaptive stress response in melanoma, which may contribute to therapy resistance.

[1]  R. Moon,et al.  WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. , 2014, The Journal of clinical investigation.

[2]  R. Bernards,et al.  Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.

[3]  D. Fisher,et al.  Molecular Pathways Molecular Pathways : BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation , 2014 .

[4]  A. Weeraratna,et al.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.

[5]  Soyoung Lee,et al.  Synthetic lethal metabolic targeting of cellular senescence in cancer therapy , 2013, Nature.

[6]  S. Haferkamp,et al.  Vemurafenib induces senescence features in melanoma cells. , 2013, The Journal of investigative dermatology.

[7]  Benjamin G. Bitler,et al.  Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. , 2013, Cell reports.

[8]  J. Gil,et al.  Senescence: a new weapon for cancer therapy. , 2012, Trends in cell biology.

[9]  A. Jimeno,et al.  Vemurafenib: the road to personalized medicine in melanoma. , 2012, Drugs of today.

[10]  R. Moon,et al.  Wnt/β-Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV600E in Human Melanoma , 2012, Science Signaling.

[11]  A. Weeraratna,et al.  Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching , 2011, Pigment cell & melanoma research.

[12]  A. Kozubík,et al.  FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence , 2010 .

[13]  A. Kozubík,et al.  FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. , 2010, Bone.

[14]  Laurent Beuret,et al.  Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. , 2010, Cancer research.

[15]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[16]  Arnell Carter,et al.  The Orphan Tyrosine Kinase Receptor, ROR2, Mediates Wnt5A Signaling in Metastatic Melanoma , 2009, Oncogene.

[17]  A. Weeraratna,et al.  Wnt5A activates the calpain-mediated cleavage of filamin A. , 2009, The Journal of investigative dermatology.

[18]  B. Short.  Mina Bissell: Context is everything , 2009, The Journal of cell biology.

[19]  H. Kondoh,et al.  Senescence induction; a possible cancer therapy , 2009, Molecular Cancer.

[20]  Stephen M Hewitt,et al.  Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. , 2008, Cancer research.

[21]  S. Haferkamp,et al.  p16INK4a-induced senescence is disabled by melanoma-associated mutations , 2008, Aging cell.

[22]  R. Chung,et al.  p53 restoration leads to tumor senescence and regression: implications for cancer therapy. , 2007, Gastroenterology.

[23]  Shunpu Zhang,et al.  A comprehensive evaluation of SAM, the SAM R-package and a simple modification to improve its performance , 2007, BMC Bioinformatics.

[24]  M. Bittner,et al.  The Wnt5A/Protein Kinase C Pathway Mediates Motility in Melanoma Cells via the Inhibition of Metastasis Suppressors and Initiation of an Epithelial to Mesenchymal Transition* , 2007, Journal of Biological Chemistry.

[25]  Jane Goodall,et al.  Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.

[26]  R. Marais,et al.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.

[27]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[28]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Schmitt.  Senescence, apoptosis and therapy — cutting the lifelines of cancer , 2003, Nature Reviews Cancer.

[30]  Soyoung Lee,et al.  A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.

[31]  Li Fang,et al.  Inhibition of p21‐mediated ROS accumulation can rescue p21‐induced senescence , 2002, The EMBO journal.

[32]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[33]  L. Hayflick.  The strategy of senescence. , 1974, The Gerontologist.

[34]  R. Moon,et al.  Wnt / b-Catenin Signaling and AXIN 1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAFV 600 E in Human Melanoma , 2012 .

[35]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[36]  Benjamin G. Bitler,et al.  Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. , 2011, Cancer research.